available for iOS, Android & web
June 07, 2011
Novartis has received clearance in Europe to market its eye drug Lucentis for macular oedema secondary to retinal vein occlusion, a disease than can cause severe damage to the retina, visual impairment and ultimately blindness.
Making patients smile
Patients’ wellbeing can be just as important as
International Clinical Researcher of the Year 2016
Book your tickets today!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions